Compare Stocks

→ The only accurate crypto trading system I know … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXS Ayala Pharmaceuticals	$0.57	$0.71	$0.50 ▼ $1.95	$6.15M	1.62	21,633 shs	2,462 shs
AMPE Ampio Pharmaceuticals	$0.50 +108.3%	$1.33	$0.14 ▼ $8.30	$568K	1.95	151,690 shs	7,900 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXS Ayala Pharmaceuticals	-11.70%	-14.66%	-8.39%	-7.17%	-54.03%
AMPE Ampio Pharmaceuticals	-3.20%	-66.01%	-85.06%	-85.68%	-95.02%

Bitcoin Rockets To Record High But Buy THIS Instead (Ad)

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AMPE Ampio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXS Ayala Pharmaceuticals	2.00	Hold	N/A	N/A
AMPE Ampio Pharmaceuticals	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXS Ayala Pharmaceuticals	$3.24M	1.90	N/A	N/A	($0.61) per share	-0.94
AMPE Ampio Pharmaceuticals	N/A	N/A	N/A	N/A	$4.04 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXS Ayala Pharmaceuticals	N/A	-$7.98	N/A	∞	N/A	N/A	-2,798.92%	-195.41%	5/21/2024 (Estimated)
AMPE Ampio Pharmaceuticals	-$8.63M	-$11.01	N/A	∞	N/A	N/A	-149.00%	-103.79%	5/13/2024 (Estimated)

Latest ADXS and AMPE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/27/2024	Q4 2023	AMPE Ampio Pharmaceuticals	N/A	-$2.48	-$2.48	-$2.48	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AMPE Ampio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXS Ayala Pharmaceuticals	N/A	0.53	0.53
AMPE Ampio Pharmaceuticals	N/A	2.41	2.41

Ownership

Institutional Ownership

Company	Institutional Ownership
ADXS Ayala Pharmaceuticals	7.18%
AMPE Ampio Pharmaceuticals	5.73%

Insider Ownership

Company	Insider Ownership
ADXS Ayala Pharmaceuticals	0.63%
AMPE Ampio Pharmaceuticals	3.30%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXS Ayala Pharmaceuticals	N/A	10.75 million	10.68 million	Not Optionable
AMPE Ampio Pharmaceuticals	6	1.14 million	1.10 million	No Data

ADXS and AMPE Headlines

Source	Headline
	Ampio Pharmaceuticals (NYSE:AMPE) Earns Sell Rating from Analysts at StockNews.com americanbankingnews.com - April 13 at 2:24 AM
	Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation finance.yahoo.com - April 3 at 2:37 PM
	Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation prnewswire.com - April 3 at 2:33 PM
	AMPE Stock Earnings: Ampio Pharmaceuticals Reported Results for Q4 2023 investorplace.com - March 27 at 11:03 PM
	Ampio Pharmaceuticals Inc money.usnews.com - March 26 at 2:08 PM
	Ampio prepares to wind down after final therapeutic dream dies fiercebiotech.com - March 26 at 9:39 AM
	Ampio Pharmaceuticals, Inc.: Ampio Announces Voluntary Delisting and SEC Deregistration finanznachrichten.de - March 26 at 9:08 AM
	US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings msn.com - March 26 at 9:08 AM
	Ampio Announces Voluntary Delisting and SEC Deregistration finance.yahoo.com - March 25 at 5:28 PM
	Ampio Pharmaceuticals, Ironwood, Incannex among healthcare movers msn.com - February 29 at 10:23 AM
	Ampio Pharmaceuticals, Inc.: Ampio Provides Update on Results from Pre-IND Enabling Studies finanznachrichten.de - February 15 at 9:58 AM
	Ampio Provides Update on Results from Pre-IND Enabling Studies prnewswire.com - February 14 at 5:45 PM
	Ampio Pharmaceuticals Announces At-The-Market Stock Offering msn.com - January 26 at 9:38 AM
	Sociedad Quimica Y Minera de Chile, Altice USA, Cingulate among premarket gainers' pack seekingalpha.com - December 28 at 9:26 AM
	What's Going On With Ampio Pharmaceuticals Stock? msn.com - December 1 at 3:52 PM
	Redhill Biopharma, Ampio Pharmaceuticals among healthcare movers msn.com - December 1 at 11:00 AM
	Ampio Pharma (NYSE: AMPE) up 194% y’day - and down 27% after hours dhakatribune.com - December 1 at 6:00 AM
	Thinking about buying stock in Aditxt Inc, Ampio Pharmaceuticals, TOP SHIPS, Mullen Automotive, or Oatly Group benzinga.com - November 30 at 10:10 AM
	Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201 finance.yahoo.com - October 5 at 5:05 PM
	Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now finance.yahoo.com - October 4 at 7:24 AM
	Ampio Pharmaceuticals to Present at the Emerging Growth Conference finance.yahoo.com - September 26 at 9:42 AM
	Understanding the Risks of Investing in Ampio Pharmaceuticals Inc. (AMPE) knoxdaily.com - September 12 at 3:24 PM
	Ampio Pharmaceuticals (AMPE) Stock Tanks Today after Treatment Fails To Reach Primary Endpoint thestreet.com - September 7 at 7:46 AM
	Ampio Pharmaceuticals Inc. [AMPE] short interest surges, jumping by 0.42 million million shares knoxdaily.com - September 1 at 3:32 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Ayala Pharmaceuticals

NASDAQ:ADXS

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Ampio Pharmaceuticals

NYSE:AMPE

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial